Royalty Pharma (RPRX)
Royalty Pharma (RPRX) Stock Price, Analysis & Data
| Bid | 53.48 |
| Market Cap | 33.86B |
| Revenue (ttm) | 2.54B |
| Net Income (ttm) | 811.99M |
| Beta | 0.42 |
| EPS (ttm) | 1.86 |
| PE Ratio (ttm) | 31.51 |
| Forward PE | 10.21 |
| P/B (ttm) | 3.77 |
| P/S (ttm) | 13.35 |
| Earnings Date | Nov 4, 2026 |
| Ask | 62.84 |
| Volume | 1,543,109 |
| Avg. Volume (20D) | 3,508,200 |
| Open | 57.89 |
| Previous Close | 58.33 |
| Day's Range | 57.77 - 58.78 |
| 52-Week Range | 34.08 - 60.44 |
| Analyst | Strong Buy |
| Price Target | 65 (10.92%) |
| Dividends | $0.94 (1.6%) |
| Ex-Dividend Date | Aug 14, 2026 |
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development fundi...
Financial Performance
In 2025, Royalty Pharma's revenue was 2.38B, an increase of 5.06% compared to the previous year's 2.26B. Earnings were 770.95M, a decrease of -10.25%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for RPRX stock is "Strong Buy". The 12-month stock price forecast is 65, which is upside of 10.92% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
